Litifilimab (Biogen, Inc.) showed significant reductions in skin disease activity among patients with cutaneous lupus erythematosus (CLE), according to the Phase 2 part of the AMETHYST Phase 2/3 study (Part A), which was presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.
Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2).
Part A of AMETHYST evaluated the efficacy and safety of litifilimab through Week 24, with reductions in skin disease activity reported across several measures.
These results echo the earlier positive Phase 2 LILAC study and support the FDA Breakthrough Therapy Designation.
“We now have consistent results from two Phase 2 studies of litifilimab showing notable reductions in CLE skin disease activity, representing a significant moment for this program. I am encouraged by these results, which support the potential to bring litifilimab to patients with cutaneous lupus erythematosus, a condition where no targeted therapies are currently approved and where there are significant unmet needs,” says Joseph F. Merola, MD, Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center in Dallas, TX, in a news release. “These findings, alongside the FDA Breakthrough Therapy Designation, underscore the potential, if approved, of litifilimab for patients living with this challenging disease. In addition to the efficacy results, litifilimab demonstrated a safety profile consistent with prior studies. Importantly, this trial intentionally enrolled a globally representative population reflective of the heterogeneity of CLE, including many participants with moderate to severe disease at baseline.”
About AMETHYST
AMETHYST is an ongoing two-part, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of litifilimab compared to placebo in participants with a variety of CLE severities. Participants are randomized to receive subcutaneous treatment with litifilimab with standard of care (SoC) or placebo every four weeks in addition to SoC. All participants will receive litifilimab during the 28-week extended treatment period from Weeks 24 to 48.
The new results are from Part A of AMETHYST, Week 0 to 24.
In the study, 74% of participants are women and 33% are non-white. This demographic distribution is consistent with the epidemiology of CLE, which disproportionately affects women and diverse ethno-racial groups. The Phase 3 part of the study is ongoing, and results remain blinded.
AMETHYST Part A met its primary endpoint with litifilimab demonstrating a statistically significant 11.8% higher reduction in disease activity in people living with CLE as measured by the Cutaneous Lupus Activity Investigator’s Global Assessment Revised (CLA-IGA-R) erythema score of 0-1 (Clear/Almost Clear) at Week 16, compared to placebo (14.7% vs. 2.9%). Secondary endpoints, including the following, were not adjusted for multiplicity in Part A, and therefore statistical significance cannot be demonstrated. Litifilimab was associated with rapid and continued improvement in skin disease activity with separation from placebo observed as early as Week 4, as measured by Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-50 (CLASI-50) response through Week 24. More participants receiving litifilimab achieved a response compared to placebo (21.7% vs. 5.8%), as measured by CLASI-70 at Week 24.
CLASI-50 and CLASI-70 responses are defined as 50% and 70% improvements from baseline in CLASI-A score, respectively. Additionally, one in six participants receiving litifilimab achieved a CLASI 0-3 score, defined as no or minimal disease activity, compared to placebo at Week 24.
Safety and Tolerability
Litifilimab was generally well-tolerated in Part A of the AMETHYST study, and tolerability was consistent with the safety profile established in completed studies. Adverse events (AEs) were reported in 74.6% (44/59) and 64.7% (22/34) of participants receiving litifilimab and placebo, respectively, in the 24-week period. Most AEs were mild to moderate in severity. Serious adverse events occurred in 6.8% (4/59) and 2.9% (1/34) of participants receiving litifilimab and placebo, respectively.